PFE - Ozempic Maker Novo Nordisk Reprimanded by UK Regulators for Payment Disclosure Failures | Benzinga
Novo Nordisk A/S (NYSE:NVO), the maker of the popular obesity drug Ozempic, has been reprimanded by the U.K.’s Prescription Medicines Code of Practice Authority (PMCPA) for failing to disclose fees and expenses paid to individuals and organizations in Britain of approximately 7.8 million pounds (around $10 million) between 2020 and 2022.
On Friday, the U.K. industry body PMCPA announced that the reprimand followed a voluntary submission by Novo Nordisk regarding these payments.
Also Read: Joe Biden ...